Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
YARDLEY, Pa., March 01, 2017 -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced plans to release fourth quarter and fiscal year 2016 financial results after the market closes on March 7th.
Chief Executive Officer, David Johnson, and Chief Financial Officer, Brian Posner, will host a teleconference at 5:00 p.m. Eastern Time on March 7th to discuss the results of the quarter and to host a question and answer session. Those interested in participating on the call may dial 800-474-8920 (719-325-2249 for international callers) and provide access code 6277436 approximately 10 minutes prior to the start time. A live webcast of the call will be made available on the investor relations section of the Company’s website at http://ir.alliqua.com.
For those unable to participate, a replay of the call will be available for two weeks at 888-203-1112 (719-457-0820 for international callers); access code 6277436. The webcast will be archived on the investor relations section of Alliqua’s website.
About Alliqua BioMedical, Inc.
Alliqua is a regenerative technologies company committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua offers solutions that allow clinicians to utilize the latest advances in regenerative technologies to bring improved patient outcomes to their practices.
Alliqua currently markets the human biologic regenerative technologies, Biovance® and Interfyl®. The Company also markets its Mist Therapy System®, which uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. In addition to these technologies, Alliqua markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. The Company has locations in Yardley, Pennsylvania, Langhorne, Pennsylvania and Eden Prairie, Minnesota.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Investor Relations: Westwicke Partners on behalf of Alliqua Biomedical, Inc. Mike Piccinino, CFA +1-443-213-0500 [email protected]
